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ABSTRACT Objective. To compare the epidemiology of renal replacement therapy (RRT) for end-stage 
renal disease (ESRD) in Latin America and Europe, as well as to study differences in macro-
economic indicators, demographic and clinical patient characteristics, mortality rates, and 
causes of death between these two populations.
Methods. We used data from 20 Latin American and 49 European national and subnational 
renal registries that had provided data to the Latin American Dialysis and Renal Transplant 
Registry (RLADTR) and the European Renal Association-European Dialysis and Transplant 
Association (ERA-EDTA) Registry, respectively. The incidence and prevalence of RRT in 2013 
were calculated per million population (pmp), overall and by subcategories of age, sex, primary 
renal disease, and treatment modality. The correlation between gross domestic product and the 
prevalence of RRT was analyzed using linear regression. Trends in the prevalence of RRT 
between 2004 and 2013 were assessed using Joinpoint regression analysis.
Results. In 2013, the overall incidence at day 91 after the onset of RRT was 181 pmp for 
Latin American countries and 130 pmp for European countries. The overall prevalence was 
660 pmp for Latin America and 782 pmp for Europe. In the Latin American countries, the 
annual increase in the prevalence averaged 4.0% (95% confidence interval (CI): 2.5%-5.6%) 
from 2004 to 2013, while the European countries showed an average annual increase of 2.2% 
(95% CI: 2.0%-2.4%) for the same time period. The crude mortality rate was higher in Latin 
America than in Europe (112 versus 100 deaths per 1 000 patient-years), and cardiovascular 
disease was the main cause of death in both of those regions.
Conclusions. There are considerable differences between Latin America and Europe in the epi-
demiology of RRT for ESRD. Further research is needed to explore the reasons for these differences.
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The incidence and prevalence of renal 
replacement therapy (RRT) for end-stage 
renal disease (ESRD) in a country are in-
fluenced by various factors, including 
the distribution of the primary causes of 
kidney failure, the progression of chronic 
kidney disease (CKD), the mortality rate, 
resource availability, and national wealth 
(1–5). In Latin America, the Latin Ameri-
can Dialysis and Renal Transplant Regis-
try (RLADTR) has since 1991 collected 
data annually on  patients receiving RRT, 
via national and subnational registries. 
The European Renal Association-Euro-
pean Dialysis and Transplant Associa-
tion (ERA-EDTA) Registry has collected 
these data since 1964 in Europe. Latin 
America and Europe have different so-
cial and cultural conditions, health and 
health care policies, and economic situa-
tions (6, 7). Comparing epidemiological 
data from these two international RRT 
registries allows us to determine differ-
ences and similarities that will help us 
understand the burden of this disease in 
these two parts of the world, and that 
could form a basis for future collabora-
tive international studies. To the best of 
our knowledge, this is the first study to 
investigate differences in the epidemiol-
ogy of RRT between Latin America and 
Europe.
The aim of this study was therefore to 
compare the incidence and prevalence 
of RRT for ESRD in Latin America and 
Europe. In addition, we looked at differ-
ences in macroeconomic indicators, 
 demographic and clinical patient charac-
teristics, RRT modalities, and causes of 
death between these two populations.
SUBJECTS AND METHODS
General population data
National macroeconomic data, life 
expectancy, and educational level cor-
responding to the year 2013 were col-
lected from the World Bank DataBank 
(8) and from the World Health Organi-
zation (WHO) (9). The following indi-
cators were collected for each country: 
life expectancy at age 65 years (the 
number of years an individual aged 65 
years would be expected to live), gross 
domestic product (GDP) per capita 
based on purchasing power parity 
(PPP) expressed in US dollars, preva-
lence of diabetes mellitus and hyper-
tension in the general population, 
public health expenditure as a percent-
age of GDP expressed in US dollars 
(percentage of GDP spent on public 
health care), and net  enrollment rate 
for secondary school (total number of 
students in the theoretical age group 
for secondary education enrolled at 
that level) expressed as a percentage of 
the total population in that age group.
Latin American Dialysis and 
Renal Transplant Registry
The RLADTR collected data on inci-
dent and prevalent patients undergo-
ing RRT in 2013 through an annual 
survey, which was completed by 20 na-
tional or subnational renal registries in 
Latin America. While 12 of these renal 
registries collected individual patient 
data, the dataset provided to RLADTR 
consisted of aggregated data for each of 
the countries. The data used for this ar-
ticle were made available by the 
RLADTR Registry Committee. Data on 
kidney transplantation were collected 
in collaboration with the Latin Ameri-
can and Caribbean Transplant Society 
(STALYC) (10).
European Renal Association-
European Dialysis and Transplant 
Association Registry
In 2015, the ERA-EDTA Registry re-
ceived the 2013 data from 49 national 
and subnational renal registries in 34 
countries in Europe or bordering the 
Mediterranean Sea (e.g., Israel, Tunisia). 
Datasets comprising individual patient 
data were received from 31 national or 
subnational renal registries in 17 coun-
tries, whereas 18 national renal registries 
contributed data in an aggregated form 
(11). Midyear population data for the 
contributing countries and country sub-
regions were derived from Eurostat (12), 
the respective national bureau of statis-
tics, or the respective national or subna-
tional renal registry.
Definitions and calculations
The incidence of RRT was defined as 
the number of patients starting RRT in 
one year (2013). and the prevalence of 
RRT was expressed as the number of pa-
tients alive and receiving RRT on 31 De-
cember 2013. Incidence and prevalence 
per million population (pmp) and per 
million age-related population (pmarp) 
were calculated by dividing the observed 
count by the midyear population.
For both international registries, the 
incidence and prevalence of RRT were 
calculated overall and by subcategories 
of age (< 65 and ≥ 65 years), sex, primary 
renal disease, and treatment modality. 
The different treatment modalities con-
sidered were hemodialysis (defined as 
in-center hemodialysis, home hemodial-
ysis, hemofiltration, and hemodiafiltra-
tion), peritoneal dialysis (defined as 
continuous ambulatory or automated 
and intermittent ambulatory or auto-
mated) and kidney transplantation (de-
fined as kidney transplanted from a 
related or unrelated living donor, de-
ceased donor, or an unknown type of 
donor) (11).
There were subtle differences in the 
coding systems used for primary renal 
diseases and causes of death between 
the two registries. To be able to compare 
the data from the two registries, we re-
grouped the primary renal diseases into 
the following five categories: glomerulo-
nephritis, diabetes mellitus, hyperten-
sion/renal vascular disease, other, and 
unknown (Supplementary Table S1). The 
causes of death were regrouped into 
the following seven categories: cardio-
vascular, cerebrovascular, infection, 
 malignancy, suicide/treatment refusal/
treatment withdrawal, miscellaneous, 
and unknown (Supplementary Table S2). 
The category of cardiovascular causes 
 included myocardial ischemia and 
 infarction, heart failure, and cardiac 
 arrest. An overview of the availability of 
data for each country is provided in Sup-
plementary Table S3. Data for the whole 
of Spain was used when available, but 
otherwise the analyses included data 
from the separate regions in Spain. For 
both of the international registries, data 
on treatment modality was recorded on 
day 91 after the onset of RRT. 
Statistical analysis
Linear regression models were used to 
explore the correlation between the GDP 
and the prevalence of RRT in the coun-
tries in Europe and Latin America.
For those countries that had data avail-
able on the prevalence of RRT for the pe-
riod from 2004 to 2013 (Supplementary 
Table S3), we examined trends over time 
in the prevalence, using Joinpoint 
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regression analysis. These analyses were 
based on Poisson regression and were 
performed using the Joinpoint 4.0.4 soft-
ware (13). The trends over time are pre-
sented as annual percentage change 
(APC) with 95% confidence interval (CI). 
Causes of death were analyzed for those 
countries reporting less than 50% of the 
causes missing or unknown.
With the exception of the Joinpoint re-
gression analysis, the statistical analyses 
were performed using SPSS version 21 
software (IBM Corporation, Armonk, 
New York, United States of America).
RESULTS 
General population data
The data from 20 countries/subre-
gions in Latin America covered 80% of 
the Latin American general population, 
while the 49 countries/subregions in 
 Europe represented 79% of the Euro-
pean general population. The median 
life  expectancy at the age of 65 years 
was 9 years for the Latin American 
countries and 14 years for the European 
countries. The GDP per capita was twice 
as high in the European countries as in 
the Latin American countries. The prev-
alence of diabetes mellitus in the gen-
eral population was lower in Europe 
than in Latin America, whereas the 
prevalence of hypertension was higher 
in Europe  (Table 1).
Incidence
In 2013, a total number of 145 678 pa-
tients started RRT for ESRD in the two 
international registries combined. The 
overall incidence at day 91 was 181 pmp 
for Latin America and 130 pmp for Eu-
rope. Figure 1 shows that the highest 
incidence rates were reported by two 
registries in Latin America, Jalisco 
(Mexico) and Panama, with 479 pmp 
and 474 pmp, respectively. Paraguay 
and Montenegro reported the lowest in-
cidence rates, with less than 25 pmp 
each. In both Latin America and Europe, 
the majority of patients were male, 55% 
(71.7 pmp) and 62% (79.3 pmp), respec-
tively. Of the incident patients in Latin 
America, 38.3% (695.3 pmarp) were 
aged over 65 years, and in Europe 56.2% 
(467.5 pmarp) were aged over 65 years. 
Nicaragua (112.7 pmarp) and Paraguay 
(168.4 pmarp) were the countries with 
the lowest incidence rates among pa-
tients older than 65 years, whereas 
Dutch- and French-speaking Belgium 
(612 and 628 pmarp, respectively) and 
Greece (641 pmarp) reported the highest 
incidence in this age group.
Both the unadjusted incidence of pa-
tients receiving dialysis and the inci-
dence of kidney transplantation were 
higher in Latin America than in Europe 
(Figure 1). The highest transplant rates at 
day 91 of RRT were found in Jalisco 
(Mexico) (58 pmp), Uruguay (32 pmp), 
and Argentina (30 pmp).
Figure 2 shows the incidence by the 
primary renal disease (PRD). Diabetes 
mellitus had the highest incidence rate 
in both regions, but the incidence rate 
was almost twice as high in Latin Amer-
ica as in Europe (42 pmp versus 26 
pmp). The incidence of other primary 
renal diseases was similar for Latin 
America and Europe.
Prevalence
On 31 December 2013, a total of 
799 296 patients with ESRD were re-
ceiving RRT in all registries reporting 
to RLADTR and the ERA-EDTA Regis-
try, corresponding to an unadjusted 
prevalence of 660 pmp for Latin Amer-
ica and of 782 pmp for Europe (Supple-
mentary Table S4). The prevalence was 
highest in  Puerto Rico and Portugal 
(1 847 and 1 749 pmp, respectively), 
while the lowest prevalence was found 
in Paraguay and Ukraine (less than 200 
pmp each). Males accounted for 57% of 
the prevalent RRT patients in Latin 
America (287 pmp) and 60% in Europe 
(667 pmp). 
In the Latin American countries, he-
modialysis was the most common 
treatment modality (66%, 436 pmp), 
whereas 10% (67 pmp) were treated 
with peritoneal dialysis, and 24% (157 
pmp) had a functioning kidney trans-
plant. In the European countries, most 
patients were treated with hemodialy-
sis (58%, 456 pmp) or had a functioning 
transplant (36%, 281 pmp). The five 
countries and subregions with the 
highest prevalence of peritoneal dialy-
sis all belong to Latin America, with 
Jalisco (Mexico) (487 pmp) in the lead. 
The prevalence of diabetes mellitus as 
a primary cause of ESRD was higher in 
Latin American countries (147 pmp) than 
in European countries (114 pmp) (data 
not shown). Puerto Rico reported the 
highest prevalence (644 pmp) of diabetes 
mellitus as a primary renal disease and 
Ukraine the lowest prevalence (21 pmp).
As is shown in Figure 3, we found a 
positive correlation between GDP per 
 capita (in terms of PPP in US$) and the 
prevalence of RRT in 2013, with a higher 
prevalence of RRT in countries with a 
larger GDP. In Latin America, the RRT 
TABLE 1. Characteristics of the Latin American Dialysis and Transplant Registry 
(RLADTR) and the European Renal Association-European Dialysis and Transplant 
Association (ERA-EDTA) registry, as well as of the general population and the 
macroeconomic situation in the countries of Latin America and Europe covered by 
those two registries
Indicator Latin America Europe
Registry countries/subregions with individual data (no.) 0 17a
Registry countries/subregions with aggregated data (no.) 20 18
General population covered by registry (percent) 80% 79%
Life expectancy at 65 yearsb; median (IQR)c (years) 9 (9–12) 14 (10–16)
Prevalence of diabetes mellitus in general populationd (percent) 8.6% 5.6%
Prevalence of hypertension in general populationd (percent) 21.8% 24.0%
GDPe per capita, PPP,f in US$,b median (IQR) 12 520 
(8 197 to 19 354)
26 200
(18 977 to 38 166)
Health expenditure, public,b percent of GDP 4.5% 6%
Net enrollment rate for secondary school, both sexesb (percent) 74% 92%
Source: Prepared by the authors, using study data.
a For ERA-EDTA, individual patient data were received from 31 national and subnational registries in 17 countries 
(Supplementary Table S3).
b Data from the World Bank, corresponding to 2013.
c IQR = interquartile range.
d Data from the World Health Organization.
e GDP = gross domestic product.
f PPP = purchasing power parity.
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prevalence increased by 43 pmp for ev-
ery US$ 1 000 increase in GDP per capita 
(95% confidence interval (CI): 
28–59). Within Europe, this association 
was weaker; for each standard deviation 
 increase in GDP per capita, the RRT 
prevalence increased by 8 pmp 
(95% CI: 1.0–16). 
Trends in prevalence over time
We observed a consistent growth in 
the prevalence of RRT over the 10-year 
time frame (Figure 4). In the Latin Amer-
ican countries, the annual increase in the 
prevalence averaged 4.0% (95% CI: 2.5%-
5.6%) from 2004 to 2013, while the 
European countries showed an average 
annual increase of 2.2% (95% CI: 2.0%-
2.4%) for the same time period.
Mortality rate and causes of death
In 2013, the mortality rate was 112 
deaths per 1 000 patient-years in Latin 
FIGURE 1. Unadjusted incidence rates per million population (pmp) of patients under renal replacement therapy, by treatment 
modality at day 91 in Latin America (A) and Europe (B) 
Source: Prepared by authors, using study data.
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America and 100 deaths per 1 000 pa-
tient-years in Europe. Cardiovascular 
disease was the leading cause of death in 
both regions, representing 35% of the 
deaths in Latin America and 30% of the 
deaths in Europe, followed by infectious 
diseases and unknown causes (Figure 5).
DISCUSSION
Our results show that there are pro-
found differences in the incidence and 
prevalence of RRT for ESRD between 
Latin America and Europe. We found a 
higher overall incidence of RRT in Latin 
America than in Europe. Although the 
subregion and the territories with the 
highest incidence (Jalisco (Mexico), Pan-
ama, and Puerto Rico) have not yet ex-
tended their health insurance coverage 
to 100% of the population, they do have 
programs for timely detection and treat-
ment of CKD. However, there is no data 
available on important variables, such 
as age at the onset of RRT, primary renal 
disease, and mortality. This lack of data 
makes it difficult to explain the ex-
tremely high incidence rates in these 
particular territories/subregions. While 
a high prevalence of CKD stage 4 could 
potentially explain this finding, only a 
few countries in both the regions have 
data available on the stages of CKD be-
fore reaching ESRD. Colombia and 
Chile reported a prevalence of 1.0% and 
0.3%, respectively, for CKD stage 4 (14–
15). Moreover, investigators from Brazil 
recently published results from the 
ELSA cohort, including a prevalence of 
4.8% for CKD stages 3, 4, and 5 com-
bined in their country (16). Similarly, 
various European countries (Italy, Nor-
way, Spain, Switzerland, and Turkey) 
reported a prevalence below 1% for 
CKD stage 4 (17–21). In order to per-
form reliable  comparisons of the preva-
lence of CKD stage 4, more detailed data 
from a greater number of countries is 
needed.
In contrast, the incidence of RRT in 
patients above the age of 65 years is 
lower in Latin America than in Europe; 
the lower overall life expectancy in 
Latin America may play an important 
role in this difference. In addition, not 
all patients in Latin America may have 
access to dialysis treatment, while Euro-
pean nephrologists might be increas-
ingly willing to start RRT in older 
patients. This means that the reported 
incidence of RRT may be an underesti-
mation of the incidence of ESRD in Latin 
America, increasing the difference with 
Europe even further.
Kidney transplantation is more com-
mon in Europe, although this treatment 
modality is feasible and available in all 
Latin American countries. Nevertheless, 
hemodialysis is by far the most common 
RRT modality in Latin America. The 
 difference between the two regions 
could be partly explained by a potential 
underestimation of patients with a func-
tioning allograft in Latin America (10), 
due to underreporting of transplant 
 procedures and/or the prevalence of 
functioning grafts. 
In both regions, diabetes mellitus is 
the most common primary renal dis-
ease. However, the incidence of diabetes 
mellitus as a cause of ESRD in Latin 
America is almost twice as high as the 
incidence in Europe, probably because 
diabetes is more prevalent within the 
general population in Latin America. 
Furthermore, obesity is more prevalent 
in Latin America (9), which could lead 
to a higher incidence of diabetes. Con-
versely, in Latin America, the incidence 
of glomerulonephritis as a cause of re-
nal failure is lower than in Europe. Glo-
merulonephritis may be underdiagnosed 
in the Latin American countries due to 
FIGURE 2. Unadjusted incidence rates per million population (pmp) and as a 
percentage, by primary renal disease (PRD) in Latin America (A) and Europe (B)a
Source: Prepared by the authors, using study data.
a For Europe, the figures are based on data from all countries/subregions except for the Czech Republic. For 
Latin America, the figures are based on data from Argentina, Bolivia, Ecuador, Guatemala, Paraguay, Peru, and 
Uruguay (Supplementary Table S3). 
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late referral to nephrologists, which in 
turn limits the possibility of performing 
a kidney biopsy (10). The proportion of 
patients with an unknown primary re-
nal disease was higher in Latin America 
than in Europe. A lower frequency of 
kidney biopsy and the introduction of a 
new entity called Mesoamerican neph-
ropathy might play a role. This disease 
predominantly affects young male agri-
cultural workers from communities 
along the Pacific coast, especially those 
working in sugarcane fields (22–25). The 
cause of this disorder is still unknown.
In contrast with incidence, the preva-
lence of RRT for ESRD is higher in the 
European countries. This might in part 
be explained by somewhat lower crude 
mortality rates and the decades-long 
tradition of kidney transplantation in 
Europe. The size of the difference in pa-
tient survival between the two regions 
could be demonstrated by performing 
survival analyses while adjusting for 
potential confounders. However, it was 
not possible to perform these analyses 
because individual patient data was un-
available for the Latin American coun-
tries and was only available for some 
European countries. Previous studies 
have shown a relationship between the 
prevalence of RRT for ESRD and the 
number of  nephrologists in a country 
(26, 27). Although data on the number 
of nephrologists per country was not 
available, lower numbers of nephrolo-
gists in Latin American countries could 
contribute to the difference in 
prevalence.
Hemodialysis was the most prevalent 
treatment of first choice in the Latin 
American countries, whereas in Euro-
pean countries the most common were 
kidney transplantation or hemodialysis. 
Peritoneal dialysis, although still under-
utilized, has a higher prevalence in the 
Latin American countries than in the Eu-
ropean countries, possibly because many 
patients live further away from their 
treatment center (26–28). For these pa-
tients, a home-based dialysis treatment is 
FIGURE 3. Association between gross domestic product (GDP) per capita and  prevalence of renal replacement therapy (RRT) 
per million population (pmp), in Latin America (A) and Europe (B)a
Source: Prepared by the authors, using study data.
a The weighted regression line in this bubble plot displays the univariate association between gross domestic product (GDP) per capita (based on purchasing power parity 
(PPP) expressed in US dollars) and the RRT prevalence. The size of marker denotes the size of the general population under study. The country abbreviations used are: 
AL, Albania; AR, Argentina; AT, Austria; BA, Bosnia and Herzegovina; BE, Belgium; BG, Bulgaria; BO, Bolivia; BR, Brazil; CH, Switzerland; CL, Chile; CO, Colombia; CR, 
Costa Rica; CU, Cuba; CZ, Czech Republic; DK, Denmark; DO, Dominican Republic; EC, Ecuador; EE, Estonia; ES, Spain (18 of 19 regions); FI, Finland; FR, France; GE, 
Georgia; GR, Greece; GT, Guatemala; HN, Honduras; HR, Croatia; IL, Israel; IS, Iceland; LT, Lithuania; LV, Latvia; ME, Montenegro; NI, Nicaragua; NL, the Netherlands; 
NO, Norway; PA, Panama; PE, Peru; PL, Poland; PR, Puerto Rico; PT, Portugal; PY, Paraguay; RO, Romania; RS, Serbia; RU, Russia; SE, Sweden; SI, Slovenia; SK, 
Slovakia; SV, El Salvador; TR, Turkey; UA, Ukraine; UK, United Kingdom; UY, Uruguay; VE, Venezuela.
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preferred. In addition, the presumed re-
duced need for trained medical staff, 
lower costs, and minimal requirement 
for technical support may play a role in 
the popularity of peritoneal dialysis in 
Latin America.
GDP per capita and public health ex-
penditure as a percent of GDP are both 
higher in the European countries. Vari-
ous reasons may account for this differ-
ence. For example, in the Latin American 
countries, an association remains be-
tween GDP and the availability of spe-
cialized medical care (29). An additional 
explanation may be the mixed model of 
the health care system (private and pub-
lic health insurance) in many of these 
countries.
Cardiovascular disease is the leading 
cause of death in the countries included 
in both registries, although in Latin 
America the rate of mortality due to car-
diovascular disease is higher (41.9 versus 
29.9 per 1 000 patient-years). This is 
probably due to a higher prevalence of 
diabetes mellitus as a cause of ESRD in 
these patients. Also, in the Latin Ameri-
can countries, there is a higher preva-
lence of diabetes, which is associated 
with increased risk of cardiovascular 
mortality. 
Finally, this study has some strengths 
and limitations that should be recog-
nized. The most important strength is 
that this is the first study comparing the 
epidemiology of RRT for ESRD between 
Latin America and Europe. The collabo-
ration between two large international 
registries led to an extremely large num-
ber of patients who could be included in 
this study. However, there were also 
some limitations. First, not all of the na-
tional/subnational registries collect indi-
vidual patient data, and in some 
countries part of the data was not avail-
able or was incomplete. As a conse-
quence, adjustment for age was not 
possible, which hampers an unbiased 
comparison of the incidence, prevalence, 
and mortality rates between the two re-
gions. The observed differences would 
probably be even larger after adjustment 
for age. We also had to reclassify the pri-
mary renal diseases and the causes of 
death. Although the differences were 
subtle, there is a possibility of misclassifi-
cation in the categories of “others” or 
“miscellaneous.”
Conclusions
This study shows that there are con-
siderable differences in the epidemiol-
ogy of RRT for ESRD between Latin 
America and Europe. In 2013, the inci-
dence of RRT was higher in Latin 
 America, while Europe had a higher 
prevalence of RRT. In both Europe and 
Latin  America, there was a positive asso-
ciation between GDP and the prevalence 
of RRT, but for Latin America a larger 
percentage of this increase could be ex-
plained by a rise in the GDP than was 
true for Europe. Finally, the mortality 
rates were higher in Latin America than 
in Europe, whereas cardiovascular dis-
ease was the most common cause of 
death in both regions. 
Some of the results found could be ex-
plained by cultural differences, health 
and health care policies, and economic 
conditions. However, we were unable to 
perform a complete analysis due to the 
wide variation in the availability of data. 
For this reason, we recommend training 
nephrologists in the creation of renal reg-
istries in those countries that do not yet 
have them, and supporting members of 
existing renal registries in improving the 
quality of the data obtained. 
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RESUMEN Objetivo. Comparar los datos epidemiológicos del tratamiento sustitutivo de la fun-
ción renal (TSFR) para la nefropatía terminal en América Latina y Europa, así como 
estudiar las diferencias en cuanto a indicadores macroeconómicos, características 
demográficas y clínicas de los pacientes, tasas de mortalidad y causas de defunción 
entre estas dos poblaciones. 
Métodos. Utilizamos los datos de 20 registros renales latinoamericanos y 49 euro-
peos, a nivel nacional y subnacional, que le habían proporcionado datos al Registro 
Latinoamericano de Diálisis y Trasplante Renal (RLADTR) y al Registro de la 
Asociación Europea Renal–Asociación Europea de Diálisis y Trasplantes (ERA-EDTA, 
por su sigla en inglés), respectivamente. Se calculó la incidencia y la prevalencia del 
TSFR en el 2013 por millón de habitantes, en total y por subcategoría (edad, sexo, 
nefropatía primaria y modalidad de tratamiento). Se analizó la correlación entre el 
producto interno bruto y la prevalencia de TSFR mediante regresión lineal. Se evalua-
ron las tendencias en la prevalencia de TSFR entre el 2004 y el 2013 mediante un aná-
lisis de regresiones lineales segmentadas. 
Resultados. En el 2013, la incidencia general al día 91 después de iniciar el trata-
miento sustitutivo de la función renal era de 181 por millón de habitantes en los países 
latinoamericanos y de 130 en los países europeos. La prevalencia general era de 660 
por millón de habitantes para América Latina y de 782 para Europa. En los países 
latinoamericanos, el aumento anual promedio de la prevalencia fue de 4,0% (intervalo 
de confianza de 95% [IC]: 2,5%-5,6%) entre el 2004 y el 2013, mientras que los países 
europeos registraron un aumento anual promedio de 2,2% (IC de 95%: 2,0%-2,4%) 
durante el mismo período. La tasa bruta de mortalidad fue mayor en América Latina 
que en Europa (112 defunciones por 1 000 años-paciente, en comparación con 100 
defunciones), y las enfermedades cardiovasculares fueron la principal causa de muerte 
en ambas regiones.
Conclusiones. Hay considerables diferencias entre América Latina y Europa en 
cuanto a los datos epidemiológicos del tratamiento sustitutivo de la función renal para 
la nefropatía terminal. Es necesario hacer más investigaciones para explorar las razo-
nes de tales diferencias.
Palabras clave Fallo renal crónico; diálisis; trasplante de riñón; mortalidad; terapia de reemplazo renal; 
América Latina; Europa (continente).
Datos epidemiológicos del 
tratamiento sustitutivo de 
la función renal en dos 
partes del mundo:  el 
Registro Latinoamericano 
de Diálisis y Trasplante 
Renal frente al Registro de 
la Asociación Europea de 
Nefrología y Asociación 
Europea de Diálisis y 
trasplante
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RESUMO Objetivo. Comparar o perfil epidemiológico de pacientes com doença renal em está-
gio final (DREF) em terapia renal substitutiva (TRS) na América Latina e na Europa e 
examinar as diferenças nos indicadores macroeconômicos, características demográfi-
cas e clínicas, taxas de mortalidade e causas de morte entre as duas populações de 
pacientes.
Métodos. O estudo foi baseado em informação de 20 registros latino-americanos e 49 
registros nacionais e subnacionais europeus que haviam fornecido dados ao 
Registro Latino-Americano de Diálise e Transplante Renal (RLADTR) e Registro da 
Associação Europeia de Nefrologia e Associação Europeia de Diálise e Transplante 
(ERA-EDTA), respectivamente. A incidência e a prevalência de TRS em 2013 foram 
calculadas por milhão de habitantes (pmh), geral e por subcategorias de idade, sexo, 
doença renal primária e modalidade de tratamento. A correlação entre o produto 
interno bruto (PIB) e a prevalência de TRS foi analisada com o uso de regressão linear. 
Tendências na prevalência de TRS entre 2004 e 2013 foram analisadas com o uso de 
regressão linear segmentada.
Resultados. Em 2013, a incidência geral ao dia 91 do início de TRS foi 181 pmh nos 
países latino-americanos e 130 pmh nos países europeus. Observou-se uma prevalên-
cia geral de TRS de 660 pmh na América Latina e 782 pmh na Europa. No período 
2004–2013, o aumento médio anual da prevalência foi de 4,0% (intervalo de confiança 
de 95% [IC 95%] 2,5%–5,6%) nos países latino-americanos, enquanto que houve um 
aumento médio anual de 2,2% (IC 95% 2,0%–2,4%) nos países europeus. A taxa de 
mortalidade bruta foi maior na América Latina que na Europa (112 versus 100 óbitos 
por 1.000 pacientes-anos) e doença cardiovascular foi a principal causa de morte em 
ambas as regiões.
Conclusões. Existem diferenças consideráveis entre a América Latina e a Europa no 
perfil epidemiológico dos pacientes com DREF em TRS. Outras pesquisas devem ser 
realizadas para investigar mais a fundo estas diferenças.
Palavras-chave Falência renal crônica; diálise; transplante de rim; mortalidade; terapia de substituição 
renal; América Latina; Europa (continente).
Epidemiologia da terapia 
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